![Kirsten Soendersted Olsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kirsten Soendersted Olsen
Director/Miembro de la Junta en Moroxite F AB .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Semmy Rülf | M | 74 |
Moroxite F AB
![]() Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | - |
Ola Harald Erici | M | 64 |
Moroxite F AB
![]() Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | - |
Anna Gisselsson | F | - |
Moroxite F AB
![]() Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | - |
Kristina Tägil | F | - |
Moroxite F AB
![]() Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 4 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones